Alzheimer’s disease (AD) primarily affects older adults. In this report, we present the
case of a 19-year-old male with gradual memory decline for 2 years and World Health
Organization-University of California Los Angeles Auditory Verbal Learning Test (WHO-UCLA
AVLT) results also showing memory impairment. Positron emission tomography-magnetic
resonance imaging with 18F fluorodeoxyglucose revealed atrophy of the bilateral
hippocampus and hypometabolism in the bilateral temporal lobe. Examination of the
patient’s cerebrospinal fluid showed an increased concentration of p-tau181 and a
decreased amyloid-β 42/40 ratio. However, through whole-genome sequencing, no known gene
mutations were identified. Considering the above, the patient was diagnosed with probable
AD.
QinQ, YinY,
WangY, LuY,
TangY, JiaJ
(2020) Gene mutations associated with early onset familial
Alzheimer’s disease in China: An overview and current status,
Mol Genet Genomic Med8, e1443.
2.
AgueroP, SainzMJ, TellezR, LordaI,
AvilaA, Garcia-RibasG, RodriguezPP, Gomez-TortosaE
(2021) De novo PS1 mutation (Pro436Gln) in a very
early-onset posterior variant of Alzheimer’s disease associated with spasticity: A case
report. J Alzheimers Dis83, 1011–1016.
3.
YokotaO, TeradaS, IshizuH, UjikeH,
IshiharaT, NambaM,
HayashiY, NishinakaT, NambaR,
NakashimaH, UedaK,
CheclerF, KurodaS
(2003) Variability and heterogeneity in Alzheimer’s disease
with cotton wool plaques: A clinicopathological study of four autopsy
cases. Acta Neuropathol106, 348–356.
4.
FolsteinMF, FolsteinSE, McHughPR
(1975) “Mini-mental state”. A practical method for grading the
cognitive state of patients for the clinician. J Psychiatr
Res12, 189–198.
5.
NasreddineZS,
PhillipsNA, BedirianV, CharbonneauS, WhiteheadV, CollinI, CummingsJL, ChertkowH
(2005) The Montreal Cognitive Assessment, MoCA: A brief
screening tool for mild cognitive impairment. J Am Geriatr
Soc53, 695–699.
6.
GavettBE
(2015) The value of Bayes’ theorem for interpreting abnormal
test scores in cognitively healthy and clinical samples. J Int
Neuropsychol Soc21, 249–257.
7.
MajM, SatzP,
JanssenR, ZaudigM, StaraceF, D’EliaL, SughondhabiromB,
MussaM, NaberD,
NdeteiD, et
al., (1994) WHO Neuropsychiatric AIDS study,
cross-sectional phase II. Neuropsychological and neurological findings.
Arch Gen Psychiatry51, 51–61.
8.
HughesCP, BergL,
DanzigerWL, CobenLA, MartinRL
(1982) A new clinical scale for the staging of
dementia. Br J Psychiatry140, 566–572.
9.
HamiltonM
(1959) The assessment of anxiety states by
rating. Br J Med Psychol32, 50–55.
10.
HamiltonM
(1960) A rating scale for depression.
J Neurol Neurosurg Psychiatry23, 56–62.
11.
ZhouA, JiaJ
(2009) Different cognitive profiles between mild cognitive
impairment due to cerebral small vessel disease and mild cognitive impairment of
Alzheimer’s disease origin. J Int Neuropsychol Soc15, 898–905.
12.
WangJ
ZY, CuiJF, FanHZ,
ChenR, ChenN,
YaoJ, DuanJH,
JiangX, ChenY,
YanLJ, HeXL
(2015) Revision of the Wechsler Memory Scale-Fourth Edition
of Chinese version (adult battery). Chin Mental Health
J7, 53–59.
13.
Lopez-GarciaS,
Jimenez-BonillaJ,
Lopez Delgado
A, Orizaola
Balaguer P, Infante Ceberio
J, Banzo
Marraco I, Rodriguez Rodriguez
E, Sanchez-JuanP
(2019) A rare PSEN1 (Leu85Pro) mutation causing Alzheimer’s
disease in a 29-year-old woman presenting as corticobasal syndrome.
J Alzheimers Dis70, 655–658.
14.
PortetF, DauvilliersY, CampionD, RauxG,
HauwJJ, Lyon-CaenO, CamuW,
TouchonJ
(2003) Very early onset AD with a de novo mutation in the
presenilin 1 gene (Met 233 Leu). Neurology61, 1136–1137.
15.
LouF, LuoX,
LiM, RenY,
HeZ (2017)
Very early-onset sporadic Alzheimer’s disease with a de novo mutation in
the PSEN1 gene, Neurobiol Aging53, 193e191–193e195.
16.
LiuJ, WangQ,
JingD, GaoR,
ZhangJ, CuiC,
QiaoH, LiangZ,
WangC, Rosa-NetoP, WuL,
JiaJ, GauthierS
(2019) Diagnostic approach of early-onset dementia with
negative family history: Implications from two cases of early-onset Alzheimer’s disease
with de novo PSEN1 mutation. J Alzheimers Dis68, 551–558.
17.
SperlingRA, AisenPS, BeckettLA, BennettDA, CraftS,
FaganAM, IwatsuboT, JackCRJr.,
KayeJ, MontineTJ, ParkDC,
ReimanEM, RoweCC,
SiemersE, SternY,
YaffeK, CarrilloMC, ThiesB,
Morrison-BogoradM,
WagsterMV, PhelpsCH
(2011) Toward defining the preclinical stages of Alzheimer’s
disease: Recommendations from the National Institute on Aging-Alzheimer’s Association
workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers Dement7, 280–292.
18.
AlbertMS, DeKoskyST, DicksonD, DuboisB, FeldmanHH, FoxNC,
GamstA, HoltzmanDM, JagustWJ, PetersenRC, SnyderPJ, CarrilloMC, ThiesB,
PhelpsCH
(2011) The diagnosis of mild cognitive impairment due to
Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s
Association workgroups on diagnostic guidelines for Alzheimer’s disease.
Alzheimers Dement7, 270–279.
MuruganNA, NordbergA, AgrenH
(2021) Cryptic sites in tau fibrils explain the preferential
binding of the AV-1451 PET tracer toward Alzheimer’s tauopathy.
ACS Chem Neurosci12, 2437–2447.
32.
ClarkCM, PontecorvoMJ, BeachTG, BedellBJ, ColemanRE, DoraiswamyPM, FleisherAS, ReimanEM, SabbaghMN, SadowskyCH, SchneiderJA, AroraA,
CarpenterAP, FlitterML, JoshiAD, KrautkramerMJ, LuM,
MintunMA, SkovronskyDM, AV-45-A16Study
Group (2012) Cerebral PET with
florbetapir compared with neuropathology at autopsy for detection of neuritic
amyloid-beta plaques: A prospective cohort study. Lancet
Neurol11, 669–678.
33.
HatashitaS, YamasakiH, SuzukiY, TanakaK, WakebeD, HayakawaH
(2014) [18F]Flutemetamol amyloid-beta PET imaging compared
with [11C]PIB across the spectrum of Alzheimer’s disease. Eur J
Nucl Med Mol Imaging41, 290–300.
34.
JingJ, ZhangF,
ZhaoL, XieJ,
ChenJ, ZhongR,
ZhangY, DongC
(2021) Correlation between brain 18F-AV45 and 18F-FDG PET
distribution characteristics and cognitive function in patients with mild and moderate
Alzheimer’s disease. J Alzheimers Dis79, 1317–1325.
35.
CamusV, PayouxP, BarreL,
DesgrangesB, VoisinT, TauberC, La Joie
R, TafaniM, HommetC, ChetelatG, MondonK, de La Sayette
V, CottierJP, BeaufilsE, RibeiroMJ, GissotV, VierronE, VercouillieJ, VellasB, EustacheF, GuilloteauD
(2012) Using PET with 18F-AV-45 (florbetapir) to quantify
brain amyloid load in a clinical environment. Eur J Nucl Med Mol
Imaging39, 621–631.
36.
PalmqvistS, ZetterbergH, BlennowK, VestbergS, AndreassonU, BrooksDJ, OweniusR, HagerstromD, WollmerP, MinthonL, HanssonO
(2014) Accuracy of brain amyloid detection in clinical
practice using cerebrospinal fluid beta-amyloid 42: A cross-validation study against
amyloid positron emission tomography. JAMA Neurol71, 1282–1289.
37.
KranceSH, Cogo-MoreiraH, RabinJS, BlackSE, SwardfagerW,
Alzheimer’s Disease Neuroimaging Initiative (2019)
Reciprocal predictive relationships between amyloid and tau biomarkers in
Alzheimer’s disease progression: An empirical model. J
Neurosci39, 7428–7437.
ChenJ, LiY,
PirragliaE, OkamuraN, RusinekH, de Leon
MJ, Alzheimer’sDisease Neuroimaging
I (2018) Quantitative evaluation
of tau PET tracers (18)F-THK5351 and (18)F-AV-1451 in Alzheimer’s disease with
standardized uptake value peak-alignment (SUVP) normalization.
Eur J Nucl Med Mol Imaging45, 1596–1604.
40.
MeyerPF, Pichet Binette
A, GonneaudJ, BreitnerJCS, VilleneuveS
(2020) Characterization of Alzheimer disease biomarker
discrepancies using cerebrospinal fluid phosphorylated tau and AV1451 positron emission
tomography. JAMA Neurol77, 508–516.
41.
OssenkoppeleR,
ReimandJ, SmithR,
LeuzyA, StrandbergO, PalmqvistS, StomrudE, ZetterbergH,
Alzheimer’s Disease Neuroimaging Initiative, ScheltensP, DageJL,
BouwmanF, BlennowK, Mattsson-CarlgrenN,
JanelidzeS, HanssonO
(2021) Tau PET correlates with different Alzheimer’s
disease-related features compared to CSF and plasma p-tau biomarkers,
EMBO Mol Med{13, e14398.
